Palwa, Nadia M.
HRN: 14-37-45 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/27/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/28/2025
04/03/2025
IV
2.25g
Q8hrs
T/C Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes